每经AI快讯,1月23日,白云山公告,分公司白云山制药总厂的阿莫西林克拉维酸钾干混悬剂已视同通过仿制药质量和疗效一致性评价。该药品于2004年8月在国内上市,2023年9月15日获得一致性评价申请受理。2023年度该药品销售收入为人民币3,444.56万元。截至公告日,白云山制药总厂在该药品一致性评价已投入研发费用约人民币843.33万元。(文章来源:每日经济新闻)
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.